Drug Profile
EYS 606
Alternative Names: EYS-606; pEYS606Latest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Eyevensys
- Developer PulseSight Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Uveitis
Most Recent Events
- 07 Dec 2022 Phase II development is ongoing USA prior to December 2022
- 05 Oct 2021 Eyevensys completes a phase II ELECTRO trial in Uveitis in USA (Intraocular) (NCT04207983)
- 01 Jun 2021 Eyevensys completes a phase I/II trial in Uveitis in France and United Kingdom (Intraocular) (NCT03308045)